Abstract
Author's reply to Letter to the Editor. We thank Favell et al. for their interest in our Brief Report, Capture of systemic anticancer therapy use by routinely collected health datasets (2020;30(1):e3012004).1
| Original language | English |
|---|---|
| Article number | e3022014 |
| Number of pages | 4 |
| Journal | Public health research & practice |
| Volume | 30 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 30 Jun 2020 |
| Externally published | Yes |
Bibliographical note
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Licence, which allows others to redistribute, adapt and share this work non-commercially provided they attribute the work and any adapted version of it is distributed under the same Creative Commons licence terms.Keywords
- anticancer agents
- Pharmaceutical Benefits Scheme (PBS)
- chemotherapy
Fingerprint Dive into the research topics of 'Capture of systemic anticancer medicines in Pharmaceutical Benefits Scheme (PBS) data likely higher than previously reported - Authors' reply'. Together they form a unique fingerprint.
Cite this
Creighton, N., Torvonen, H. E., Zhao, G. W., & Currow, D. C. (2020). Capture of systemic anticancer medicines in Pharmaceutical Benefits Scheme (PBS) data likely higher than previously reported - Authors' reply. Public health research & practice, 30(2), [e3022014]. https://doi.org/10.17061/phrp3022014